A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease
Top Cited Papers
- 1 June 2006
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (6) , 754-759
- https://doi.org/10.1016/j.cgh.2006.03.028
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Development of an enteric-coated formulation containing freeze-dried, viable recombinant for the ileal mucosal delivery of human interleukin-10European Journal of Pharmaceutics and Biopharmaceutics, 2005
- Better living through microbesNature Biotechnology, 2005
- NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responsesNature Immunology, 2004
- Advances in the treatment of Crohn’s diseaseGastroenterology, 2004
- The immunological and genetic basis of inflammatory bowel diseaseNature Reviews Immunology, 2003
- Churning out safer microbes for drug deliveryNature Biotechnology, 2003
- Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10Nature Biotechnology, 2003
- Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gammaGut, 2002
- Interleukin-10-deficient mice develop chronic enterocolitisCell, 1993
- A host factor absent from Lactococcus lactis subspecies lactis MG1363 is required for conjugative transpositionMolecular Microbiology, 1991